ArticleAntimicrobial agents and chemotherapy2024
Prevalence of the cefazolin inoculum effect (CzIE) in nasal colonizing methicillin-susceptible
Abstract readMulticenter Study
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Development of a rapid diagnostic test for the cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus: Cefinase disk direct (CDD) test.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- The Cefazolin Inoculum Effect: An Underappreciated Factor in MSSA Treatment Strategies.Infectious diseases and therapy · 2026Review
- Optimizing cefazolin dosing for central nervous system infections: insights from population pharmacokinetics and Monte Carlo simulations.Antimicrobial agents and chemotherapy · 2025Article
- Validation of a modified rapid test to detect the cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus from bloodstream infections in hospitals from North and Latin America.The Journal of antimicrobial chemotherapy · 2025Article
Corrections and comments
- Update of
Authors and funding
22 authors.
Lina P Carvajal *Molecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia.
Sandra Rincon *Molecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia.
Sara I Gomez VillegasBrigham and Women´s Hospital, Harvard Medical School, Boston, Massachusetts, USA.
J Manuel Matiz-GonzalezMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia.
Karen OrdoñezDepartment of Infectious Diseases, ESE Hospital Universitario,San Jorge de Pereira, Pereira, Colombia.
Alejandra SantamariaDepartment of Infectious Diseases, ESE Hospital Universitario,San Jorge de Pereira, Pereira, Colombia.
Leonardo Ospina NavarroClinica Colsubsidio Calle, Bogota, Colombia.
Jaime BeltranClinica Colsubsidio Calle, Bogota, Colombia.
Fredy GuevaraServicio de Infectología, Fundación Santafe de Bogota, Bogota, Colombia.
Yardany R MendezGrupo de Investigacion en Epidemiologia Clinica de Colombia (GRECO), Universidad Pedagogica y Tecnologica de Colombia, Tunja, Colombia.
Soraya SalcedoOrganizacion Clinica General del Norte, Barranquilla, Colombia.
Alexandra PorrasLos Cobos Medical Center, Bogota, Colombia.
Albert Valencia-MorenoLos Cobos Medical Center, Bogota, Colombia.
Haley GreeniaCenter for Infectious Disease, Houston Methodist Research Institute, Houston, Texas, USA.
Alexander DeyanovCenter for Infectious Disease, Houston Methodist Research Institute, Houston, Texas, USA.
Rodrigo BaptistaCenter for Infectious Disease, Houston Methodist Research Institute, Houston, Texas, USA.
Vincent H TamDepartament of Pharmacy Practice and Translational Research, University of Houston, Houston, Texas, USA.ORCID 0000-0001-7071-5376
Diana PanessoMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia.
Truc T TranCenter for Infectious Disease, Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0000-0002-2696-4196
William R MillerCenter for Infectious Disease, Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0000-0002-1518-2973
Cesar A AriasCenter for Infectious Disease, Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0000-0001-9054-9774
Jinnethe ReyesMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia.ORCID 0000-0002-1722-0734
Funding
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SAVIDGE, TOR C. · 2020 to 2025
$12.0MVENOUS: A translational study of enterococcal bacteremiaR01AI148342 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2024
$3.9MThe LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7MClinical Impact of the Cefazolin Inoculum EffectR01AI173138 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Cesar Augusto Arias · 2023 to 2026
$2.6MPOR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5MAntimicrobial Resistance Training Program in the Texas Medical Center (AMR-TPT)T32AI179595 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Cesar Augusto Arias · 2024 to 2026
$1.0MHHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) K24AI121296HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) P01AI152999HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI134637HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI148342HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI173138HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) T32AI179595Ministerio de Ciencia, Tecnología e Innovación (Minciencias) 130880764152-CT 776-2018NIAID NIH HHS K24 AI121296NIAID NIH HHS P01 AI152999NIAID NIH HHS R01 AI134637NIAID NIH HHS R01 AI148342NIAID NIH HHS R01 AI173138NIAID NIH HHS T32 AI179595Universidad El Bosque (UEB) PCI 2023-002
Abstract
The cefazolin inoculum effect (CzIE) has been associated with poor clinical outcomes in patients with methicillin-susceptible
Indexed as
Anti-Bacterial AgentsCefazolinIntensive Care UnitsMicrobial Sensitivity TestsStaphylococcal InfectionsAdultAgedColombiaFemaleHumansMaleMethicillin-Resistant Staphylococcus aureusMiddle AgedNosePrevalenceStaphylococcus aureusAnti-Bacterial AgentsCefazolincefazolinColombiainoculum effectintensive care unitMSSA
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.